GrippeAllemagneV4, Main, Exploration, bibRecord, 000068

Direct and indirect effects of influenza vaccination.

Identifieur interne : 000068 ( Main/Exploration ); précédent : 000067; suivant : 000069

Direct and indirect effects of influenza vaccination.

Auteurs : Martin Eichner [Allemagne] ; Markus Schwehm [Allemagne] ; Linda Eichner [Allemagne] ; Laetitia Gerlier [Belgique]

Source :

BMC infectious diseases [ 1471-2334 ] ; 2017.

RBID : pubmed:28441935

Descripteurs français

KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Allemagne (épidémiologie), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (transmission), Humains (MeSH), Modèles théoriques (MeSH), Sujet âgé (MeSH), Vaccination (statistiques et données numériques), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (usage thérapeutique).
MESH :
- immunologie : Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- statistiques et données numériques : Vaccination.
- usage thérapeutique : Grippe humaine, Vaccins antigrippaux.
- épidémiologie : Allemagne.
- Adolescent, Adulte, Enfant, Enfant d'âge préscolaire, Humains, Modèles théoriques, Sujet âgé.

English descriptors

KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Child (MeSH), Child, Preschool (MeSH), Germany (epidemiology), Humans (MeSH), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (prevention & control), Influenza, Human (transmission), Models, Theoretical (MeSH), Vaccination (statistics & numerical data).
MESH :
- chemical , immunology : Influenza Vaccines.
- epidemiology : Germany.
- prevention & control : Influenza, Human.
- statistics & numerical data : Vaccination.
- chemical , therapeutic use : Influenza Vaccines.
- transmission : Influenza, Human.
- Adolescent, Adult, Aged, Child, Child, Preschool, Humans, Models, Theoretical.

Abstract

BACKGROUND

After vaccination, vaccinees acquire some protection against infection and/or disease. Vaccination, therefore, reduces the number of infections in the population. Due to this herd protection, not everybody needs to be vaccinated to prevent infections from spreading.

METHODS

We quantify direct and indirect effects of influenza vaccination examining the standard Susceptible-Infected-Recovered (SIR) and Susceptible-Infected-Recovered-Susceptible (SIRS) model as well as simulation results of a sophisticated simulation tool which allows for seasonal transmission of four influenza strains in a population with realistic demography and age-dependent contact patterns.

RESULTS

As shown analytically for the simple SIR and SIRS transmission models, indirect vaccination effects are bigger than direct ones if the effective reproduction number of disease transmission is close to the critical value of 1. Simulation results for 20-60% vaccination with live influenza vaccine of 2-17 year old children in Germany, averaged over 10 years (2017-26), confirm this result: four to seven times as many influenza cases are prevented among non-vaccinated individuals as among vaccinees. For complications like death due to influenza which occur much more frequently in the unvaccinated elderly than in the vaccination target group of children, indirect benefits can surpass direct ones by a factor of 20 or even more than 30.

CONCLUSIONS

The true effect of vaccination can be much bigger than what would be expected by only looking at vaccination coverage and vaccine efficacy.

DOI: 10.1186/s12879-017-2399-4
PubMed: 28441935
PubMed Central: PMC5405516

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000056
to stream Main, to step Curation: 000056

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Direct and indirect effects of influenza vaccination.</title>
<author><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
<affiliation wicri:level="1"><nlm:affiliation>Epimos GmbH, Dusslingen, Germany. martin.eichner@epimos.com.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Epimos GmbH, Dusslingen</wicri:regionArea>
<wicri:noRegion>Dusslingen</wicri:noRegion>
<wicri:noRegion>Dusslingen</wicri:noRegion>
<wicri:noRegion>Dusslingen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany. martin.eichner@epimos.com.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Tübingen</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schwehm, Markus" sort="Schwehm, Markus" uniqKey="Schwehm M" first="Markus" last="Schwehm">Markus Schwehm</name>
<affiliation wicri:level="1"><nlm:affiliation>ExploSYS GmbH, Leinfelden, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>ExploSYS GmbH, Leinfelden</wicri:regionArea>
<wicri:noRegion>Leinfelden</wicri:noRegion>
<wicri:noRegion>Leinfelden</wicri:noRegion>
<wicri:noRegion>Leinfelden</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Eichner, Linda" sort="Eichner, Linda" uniqKey="Eichner L" first="Linda" last="Eichner">Linda Eichner</name>
<affiliation wicri:level="1"><nlm:affiliation>Epimos GmbH, Dusslingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Epimos GmbH, Dusslingen</wicri:regionArea>
<wicri:noRegion>Dusslingen</wicri:noRegion>
<wicri:noRegion>Dusslingen</wicri:noRegion>
<wicri:noRegion>Dusslingen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gerlier, Laetitia" sort="Gerlier, Laetitia" uniqKey="Gerlier L" first="Laetitia" last="Gerlier">Laetitia Gerlier</name>
<affiliation wicri:level="1"><nlm:affiliation>QuintilesIMS, Real-World Evidence Solutions, Zaventem, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>QuintilesIMS, Real-World Evidence Solutions, Zaventem</wicri:regionArea>
<wicri:noRegion>Zaventem</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28441935</idno>
<idno type="pmid">28441935</idno>
<idno type="doi">10.1186/s12879-017-2399-4</idno>
<idno type="pmc">PMC5405516</idno>
<idno type="wicri:Area/Main/Corpus">000056</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000056</idno>
<idno type="wicri:Area/Main/Curation">000056</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000056</idno>
<idno type="wicri:Area/Main/Exploration">000056</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Direct and indirect effects of influenza vaccination.</title>
<author><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
<affiliation wicri:level="1"><nlm:affiliation>Epimos GmbH, Dusslingen, Germany. martin.eichner@epimos.com.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Epimos GmbH, Dusslingen</wicri:regionArea>
<wicri:noRegion>Dusslingen</wicri:noRegion>
<wicri:noRegion>Dusslingen</wicri:noRegion>
<wicri:noRegion>Dusslingen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany. martin.eichner@epimos.com.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Tübingen</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schwehm, Markus" sort="Schwehm, Markus" uniqKey="Schwehm M" first="Markus" last="Schwehm">Markus Schwehm</name>
<affiliation wicri:level="1"><nlm:affiliation>ExploSYS GmbH, Leinfelden, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>ExploSYS GmbH, Leinfelden</wicri:regionArea>
<wicri:noRegion>Leinfelden</wicri:noRegion>
<wicri:noRegion>Leinfelden</wicri:noRegion>
<wicri:noRegion>Leinfelden</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Eichner, Linda" sort="Eichner, Linda" uniqKey="Eichner L" first="Linda" last="Eichner">Linda Eichner</name>
<affiliation wicri:level="1"><nlm:affiliation>Epimos GmbH, Dusslingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Epimos GmbH, Dusslingen</wicri:regionArea>
<wicri:noRegion>Dusslingen</wicri:noRegion>
<wicri:noRegion>Dusslingen</wicri:noRegion>
<wicri:noRegion>Dusslingen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gerlier, Laetitia" sort="Gerlier, Laetitia" uniqKey="Gerlier L" first="Laetitia" last="Gerlier">Laetitia Gerlier</name>
<affiliation wicri:level="1"><nlm:affiliation>QuintilesIMS, Real-World Evidence Solutions, Zaventem, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>QuintilesIMS, Real-World Evidence Solutions, Zaventem</wicri:regionArea>
<wicri:noRegion>Zaventem</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">BMC infectious diseases</title>
<idno type="eISSN">1471-2334</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Germany (epidemiology)</term>
<term>Humans (MeSH)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (transmission)</term>
<term>Models, Theoretical (MeSH)</term>
<term>Vaccination (statistics & numerical data)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Allemagne (épidémiologie)</term>
<term>Enfant (MeSH)</term>
<term>Enfant d'âge préscolaire (MeSH)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Grippe humaine (transmission)</term>
<term>Humains (MeSH)</term>
<term>Modèles théoriques (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Vaccination (statistiques et données numériques)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Grippe humaine</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Humans</term>
<term>Models, Theoretical</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Humains</term>
<term>Modèles théoriques</term>
<term>Sujet âgé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>After vaccination, vaccinees acquire some protection against infection and/or disease. Vaccination, therefore, reduces the number of infections in the population. Due to this herd protection, not everybody needs to be vaccinated to prevent infections from spreading.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>We quantify direct and indirect effects of influenza vaccination examining the standard Susceptible-Infected-Recovered (SIR) and Susceptible-Infected-Recovered-Susceptible (SIRS) model as well as simulation results of a sophisticated simulation tool which allows for seasonal transmission of four influenza strains in a population with realistic demography and age-dependent contact patterns.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>As shown analytically for the simple SIR and SIRS transmission models, indirect vaccination effects are bigger than direct ones if the effective reproduction number of disease transmission is close to the critical value of 1. Simulation results for 20-60% vaccination with live influenza vaccine of 2-17 year old children in Germany, averaged over 10 years (2017-26), confirm this result: four to seven times as many influenza cases are prevented among non-vaccinated individuals as among vaccinees. For complications like death due to influenza which occur much more frequently in the unvaccinated elderly than in the vaccination target group of children, indirect benefits can surpass direct ones by a factor of 20 or even more than 30.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>The true effect of vaccination can be much bigger than what would be expected by only looking at vaccination coverage and vaccine efficacy.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28441935</PMID>
<DateCompleted><Year>2017</Year>
<Month>08</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>17</Volume>
<Issue>1</Issue>
<PubDate><Year>2017</Year>
<Month>04</Month>
<Day>26</Day>
</PubDate>
</JournalIssue>
<Title>BMC infectious diseases</Title>
<ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Direct and indirect effects of influenza vaccination.</ArticleTitle>
<Pagination><MedlinePgn>308</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-017-2399-4</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">After vaccination, vaccinees acquire some protection against infection and/or disease. Vaccination, therefore, reduces the number of infections in the population. Due to this herd protection, not everybody needs to be vaccinated to prevent infections from spreading.</AbstractText>
<AbstractText Label="METHODS">We quantify direct and indirect effects of influenza vaccination examining the standard Susceptible-Infected-Recovered (SIR) and Susceptible-Infected-Recovered-Susceptible (SIRS) model as well as simulation results of a sophisticated simulation tool which allows for seasonal transmission of four influenza strains in a population with realistic demography and age-dependent contact patterns.</AbstractText>
<AbstractText Label="RESULTS">As shown analytically for the simple SIR and SIRS transmission models, indirect vaccination effects are bigger than direct ones if the effective reproduction number of disease transmission is close to the critical value of 1. Simulation results for 20-60% vaccination with live influenza vaccine of 2-17 year old children in Germany, averaged over 10 years (2017-26), confirm this result: four to seven times as many influenza cases are prevented among non-vaccinated individuals as among vaccinees. For complications like death due to influenza which occur much more frequently in the unvaccinated elderly than in the vaccination target group of children, indirect benefits can surpass direct ones by a factor of 20 or even more than 30.</AbstractText>
<AbstractText Label="CONCLUSIONS">The true effect of vaccination can be much bigger than what would be expected by only looking at vaccination coverage and vaccine efficacy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eichner</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Epimos GmbH, Dusslingen, Germany. martin.eichner@epimos.com.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany. martin.eichner@epimos.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schwehm</LastName>
<ForeName>Markus</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>ExploSYS GmbH, Leinfelden, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Eichner</LastName>
<ForeName>Linda</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Epimos GmbH, Dusslingen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gerlier</LastName>
<ForeName>Laetitia</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>QuintilesIMS, Real-World Evidence Solutions, Zaventem, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>04</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>BMC Infect Dis</MedlineTA>
<NlmUniqueID>100968551</NlmUniqueID>
<ISSNLinking>1471-2334</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>12</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>04</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>4</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>4</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>8</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28441935</ArticleId>
<ArticleId IdType="doi">10.1186/s12879-017-2399-4</ArticleId>
<ArticleId IdType="pii">10.1186/s12879-017-2399-4</ArticleId>
<ArticleId IdType="pmc">PMC5405516</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Fam Pract. 2001 Dec;18(6):629-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11739352</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2001 Mar 22;344(12):889-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11259722</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2014 Jul 03;14:365</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24993051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Jan 30;31(6):927-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23246550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2009 Dec;64(12):1062-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19454409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Jan 26;23(10):1284-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15652671</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015;20(39):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26537222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2008 Jun;136(6):852-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17634159</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Health Econ. 2015 Jun;16(5):471-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24859492</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2010 Jan 12;10:8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20067628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Feb 1;30(6):1208-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22178725</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015 ;20(36):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26535911</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2014 Jan 22;14:40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24450996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dtsch Arztebl Int. 2010 Dec;107(48):845-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21173931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Paediatr Drugs. 2016 Aug;18(4):303-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27272706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Epidemiol. 2008 Apr 1;167(7):775-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18230677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2006 Dec;4(12):900-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17088933</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2000 Nov;19(11):834-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11152308</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Sep 26;26(41):5321-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18647634</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2004 Oct 15;190(8):1369-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15378427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Feb 11;27(7):1101-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19095024</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2010 Mar 10;303(10):943-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20215608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2008 Mar 25;5(3):e74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18366252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Feb;58(2):174-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25446313</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2000 Apr;124(2):273-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10813153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2010 Jul 07;(7):CD001269</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20614424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20166072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004879</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18425905</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2008;26(1):45-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18088158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infection. 2009 Oct;37(5):390-400</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19768382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Feb 18;23(13):1540-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15694506</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Feb 20;24(8):1047-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16298026</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2012 Aug 15;(8):CD004879</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22895945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2011 May;37(5):1151-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20817703</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Belgique</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>District de Tübingen</li>
</region>
<settlement><li>Tübingen</li>
</settlement>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
</noRegion>
<name sortKey="Eichner, Linda" sort="Eichner, Linda" uniqKey="Eichner L" first="Linda" last="Eichner">Linda Eichner</name>
<name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
<name sortKey="Schwehm, Markus" sort="Schwehm, Markus" uniqKey="Schwehm M" first="Markus" last="Schwehm">Markus Schwehm</name>
</country>
<country name="Belgique"><noRegion><name sortKey="Gerlier, Laetitia" sort="Gerlier, Laetitia" uniqKey="Gerlier L" first="Laetitia" last="Gerlier">Laetitia Gerlier</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000068 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000068 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeAllemagneV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28441935
   |texte=   Direct and indirect effects of influenza vaccination.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28441935" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV4

This area was generated with Dilib version V0.6.35.
Data generation: Mon Aug 10 17:53:30 2020. Site generation: Sat Mar 27 17:40:37 2021

	Serveur d'exploration sur la grippe en Allemagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Allemagne

Direct and indirect effects of influenza vaccination.

Direct and indirect effects of influenza vaccination.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki